Are the current recommendations for the use of aspirin in primary prevention of cardiovascular disease applicable in low-income countries?

References

• LimSSVosTFlaxmanADA comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010Lancet20123802224226023245609
   PubMed Web of Science ®Google Scholar
• World Health OrganizationAtlas of heart disease and stroke [cited February 01, 2015]. Available from: http://www.who.int/cardiovascular_diseases/resources/atlas/en/Accessed August 7, 2015
   Google Scholar
• World Health OrganizationNeglected global epidemics: three growing threatsShaping the FutureThe World Health ReportGenevaWorld Health Organization20038595
   Google Scholar
• MendisSAl BashirIDissanayakeLGaps in capacity in primary care in low-resource settings for implementation of essential noncommunicable disease interventionsInt J Hypertens2012201258404123251789
   PubMedGoogle Scholar
• Biondi-ZoccaiGWuYSerranoCVJrFratiGAgostoniPAbbateAAspirin underuse, non-compliance or cessation: definition, extent, impact and potential solutions in the primary and secondary prevention of cardiovascular diseaseInt J Cardiol2014182C14815425577751
   PubMedGoogle Scholar
• CohenATImfeldSMarkhamJGranzieraSThe use of aspirin for primary and secondary prevention in venous thromboembolism and other cardiovascular disordersThromb Res2015135221722525541030
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists’ (ATT) Collaboration; BaigentCBlackwellLAspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsLancet20093731849186019482214
   PubMed Web of Science ®Google Scholar
• VandvikPOLincoffAMGoreJMPrimary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest20121412 Suppl637S668S
   Web of Science ®Google Scholar
• BartolucciAATenderaMHowardGMeta-analysis of multiple primary prevention trials of cardiovascular events using aspirinAm J Cardiol20111071796180121481826
   PubMed Web of Science ®Google Scholar
• RajuNSobieraj-TeagueMHirshJO’DonnellMEikelboomJEffect of aspirin on mortality in the primary prevention of cardiovascular diseaseAm J Med201112462162921592450
   PubMed Web of Science ®Google Scholar
• PignoneMAlbertsMJColwellJAAspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology FoundationCirculation20101212694270120508178
   PubMed Web of Science ®Google Scholar
• De BerardisGLucisanoGD’EttorreAAssociation of aspirin use with major bleeding in patients with and without diabetesJAMA20123072286229422706834
   PubMed Web of Science ®Google Scholar
• IkedaYShimadaKTeramotoTLow-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trialJAMA20143122510252025401325
   PubMed Web of Science ®Google Scholar
• SutcliffePConnockMGurungTAspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviewsHealth Technol Assess201317431253
   Web of Science ®Google Scholar
• DeptaJPBhattDLShould patients stop taking aspirin for primary prevention?Cleve Clin J Med2015822919625897597
   PubMed Web of Science ®Google Scholar
• BattistoniAMastromarinoVVolpeMReducing cardiovascular and cancer risk: how to address global primary prevention in clinical practiceClin Cardiol201538638739425873555
   PubMed Web of Science ®Google Scholar
• HalvorsenSAndreottiFten BergJMAspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosisJ Am Coll Cardiol201464331932725034070
   PubMed Web of Science ®Google Scholar
• GBD 2013 Mortality and Causes of Deaths CollaboratorsGlobal, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013Lancet2015385996311717125530442
   PubMed Web of Science ®Google Scholar
• RidkerPMCookNRLeeIMA randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in womenN Engl J Med2005352131293130415753114
   PubMed Web of Science ®Google Scholar
• DeFilippisAPYoungRCarrubbaCJAn analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohortAnn Intern Med2015162426627525686167
   PubMed Web of Science ®Google Scholar
• YusufSHawkenSOunpuuSEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control studyLancet200436493795215364185
   PubMed Web of Science ®Google Scholar
• McGorrianCYusufSIslamSEstimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk ScoreEur Heart J20113258158921177699
   PubMed Web of Science ®Google Scholar
• YusufSRangarajanSTeoKCardiovascular risk and events in 17 low-, middle-, and high-income countriesN Engl J Med201437181882725162888
   PubMed Web of Science ®Google Scholar
• NoubiapJJEssoumaEBignaJJTargeting household air pollution for curbing the cardiovascular disease burden: a health priority in sub-Saharan AfricaJ Clin Hypertens Epub2015713
   Web of Science ®Google Scholar
• JingiAMNoubiapJJEwane OnanaAAccess to diagnostic tests and essential medicines for cardiovascular diseases and diabetes care: cost, availability and affordability in the West Region of CameroonPLoS One20149e11181225369455
   PubMed Web of Science ®Google Scholar